World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   1455 records for 366 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4 5 6 7 8 9 10 Last
Recruitment statusProspective RegistrationMain ID Public TitleDate of Registration
RecruitingYesNCT03147898
Observational Study Describing the Immune Profile Induced By Pertussis Vaccines
08/05/2017
Not recruitingNoNCT03130673
Challenges of Hip Fracture Care in Developing Countries. Experience at a Level 3 Center in Panama
22/04/2017
AuthorisedYesEUCTR2016-002733-30-ES
A study to evaluate the safety, reactogenicity nad immunogenicity of the GSK investigational vaccine GSK3003891A in healthy pregnant women and infants born to vaccinated mothers 08/02/2017
Not recruitingNoNCT03027297
TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV
19/01/2017
Not recruitingNoNCT03028194
Postpartum Uterine Curettage in the Recovery From Preeclampsia/Eclampsia
18/01/2017
RecruitingYesNCT03025750
Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age
16/01/2017
RecruitingYesNCT02984423
FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study
23/11/2016
AuthorisedYesEUCTR2016-003467-19-GB
safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre / postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2016-003467-19-PTsafety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease14/12/2016
AuthorisedEUCTR2016-003467-19-ESSafety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease10/02/2017
AuthorisedEUCTR2016-003467-19-NLsafety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease23/11/2016
AuthorisedEUCTR2016-003467-19-HUsafety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease25/11/2016
AuthorisedEUCTR2016-003467-19-GRsafety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease03/01/2017
AuthorisedEUCTR2016-003467-19-BGsafety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease07/12/2016
AuthorisedEUCTR2016-003467-19-DKsafety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease16/02/2017
AuthorisedEUCTR2016-003467-19-ATsafety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease03/02/2017
AuthorisedEUCTR2016-003467-19-SIsafety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease09/05/2017
07/11/2016
RecruitingYesNCT02948829
Safety and Immunogenicity of Takeda's TDV in Healthy Children
26/10/2016
RecruitingYesNCT02945657
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
21/10/2016
     
1 2 3 4 5 6 7 8 9 10 Last
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.3 - Version history